CTOs on the Move

NMD Pharma

www.nmdpharma.com

 
NMD Pharma A/S is a clinical-stage biotech company developing a first-in-class platform of small molecule therapies selectively targeting the skeletal muscle chloride ion channel (ClC-1) for the treatment of severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform leveraging the in-depth know-how of muscle physiology and muscular disorders, small molecule modulators, enabling technologies and tools as well as in vivo ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

CMAC Consultancy

CMAC Consultancy is a Vernon Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioTechniques

BioTechniques is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GangaGen Inc

GangaGen Inc is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Business Resources

Medical Business Resources, Inc., established in 1994 as a medical billing service, offers a cost effective solution to the complexities of medical practice administration. Our services allow providers to focus upon delivering health care with the confidence that administrative support services are in place.

Personalis

Personalis, Inc. is partnering with biopharma to develop and commercialize the next generation of cancer immunotherapies. We provide advanced genomic sequencing and analytics for immuno-oncology. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products and makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions often missed with the use of conventional sequencing techniques, for more comprehensive and accurate genomic data. ACE ImmunoID, our universal platform for immuno-oncology, combines augmented whole exome and transcriptome assays with analytics that capture neoantigens, elucidate the tumor microenviroment, and identify mechanisms of tumor escape.